News Novo Nordisk's fling with Hims & Hers ends in a bust-up The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.
News Digital health firm Omada prices $150m IPO In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion.
News Hims & Hers buys Zava to form European beachhead US telehealth company Hims & Hers has reached a deal to buy its UK counterpart Zava as part of a broader push into Europe.
News Novo Nordisk unleashes Wegovy telehealth blitz Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.
News Lilly adds Alzheimer's to its DTC platform LillyDirect Eli Lilly's DTC platform LillyDirect has been expanded to include in-person and telehealth services for people in the US living with Alzheimer's.
News Pharma group slams Hims & Hers over Super Bowl GLP-1 ad Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face